Answers are grounded in this paper and cite their sources.
Purpose: The epithelial-to-mesenchymal transition (EMT) is the main event that favors cell migration and metastasis in breast cancer.Previously, we demonstrated that 1 nM estradiol (E 2 ) promotes EMT, induced by c-Src kinase, causing changes in the localization of proteins that compose the tight junction (TJ) and adherens junction (AJ).Methods: The present work highlights the central role of c-Src in the initiation of metastasis, induced by E 2 , through increasing the ability of MCF-7 and T47-D cells, which express estrogen receptor alpha (ERα), to migrate and invade before they become metastatic.Results: Treatment with E 2 can activate two signaling pathways, the first one by the phosphorylated c-Src (p-Src) which forms the p-Src/E-cadherin complex.This phenomenon was completely prevented by incubation with a selective inhibitor of c-Src (5 µM PP2).p-Src then promotes the downregulation of E-cadherin and occludin, which are epithelial phenotype marker proteins of the AJ and TJ, respectively.In the second pathway, E 2 binds to ERα, creating a complex that translocates to the nucleus, inducing the synthesis of SNAIL1 and N-cadherin proteins, markers of the mesenchymal phenotype.Both processes increased the migratory and invasive capacities of both cell lines.Conclusion: The present study demonstrate that E 2 enhance EMT and migration, through c-Src activation, in human breast cancer cells that express ERα and become potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Jiménez-Salazar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: